Clinical Trial Update: PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) [Phase 1, Phase 2]

View source ↗

Summary

An update on a Phase 1/Phase 2 trial evaluating neoadjuvant TAMP (PRISM-TAMP) for pancreatic ductal adenocarcinoma, with attention to tumor regression and intra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma
• Pancreatic Neoplasms

Drugs mentioned

• PRISM-TAMP

Snippet

Sponsor: University of Vermont | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING